key: cord-0885416-1t1trqy2
authors: Winkler, Emma S.; Gilchuk, Pavlo; Yu, Jinsheng; Bailey, Adam L.; Chen, Rita E.; Chong, Zhenlu; Zost, Seth J.; Jang, Hyesun; Huang, Ying; Allen, James D.; Case, James Brett; Sutton, Rachel E.; Carnahan, Robert H.; Darling, Tamarand L.; Boon, Adrianus C.M.; Mack, Matthias; Head, Richard D.; Ross, Ted M.; Crowe, James E.; Diamond, Michael S.
title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
date: 2021-02-12
journal: Cell
DOI: 10.1016/j.cell.2021.02.026
sha: 3c4c83bac41da84c77416f4a24791e6def038061
doc_id: 885416
cord_uid: 1t1trqy2

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here we define correlates of protection of neutralizing human monoclonal antibodies (mAbs) in SARS-CoV-2-infected animals. Whereas Fc effector functions are dispensable when representative neutralizing mAbs are administered as prophylaxis, they are required for optimal protection as therapy. When given after infection, intact mAbs reduce SARS-CoV-2 burden and lung disease in mice and hamsters better than loss-of-function Fc variant mAbs. Fc engagement of neutralizing antibodies mitigates inflammation and improves respiratory mechanics, and transcriptional profiling suggests these phenotypes are associated with diminished innate immune signaling and preserved tissue repair. Immune cell depletions establish that neutralizing mAbs require monocytes and CD8+ T cells for optimal clinical and virological benefit. Thus, potently neutralizing mAbs utilize Fc effector functions during therapy to mitigate lung infection and disease.

RNA was more focal in the lungs of mice receiving intact COV2-2050 at D+2 with evidence of 150 cleared regions and a smaller affected proportion (Fig 2H) . Additionally, K18-hACE2 mice 151 receiving intact COV2-2050 at D+2, but not COV2-2050 LALA-PG, showed functional 152 improvement in pulmonary mechanics (e.g., inspiratory capacity, resistance, and elastance), 153 and lung compliance and distensibility (Fig 2I-J) .

To expand on these results, we tested the therapeutic activity of three additional neutralized SARS-CoV-2 equivalently compared to parental COV2-2072 human IgG1 mAb ( Fig  S1A) . As expected, mIgG1 and mIgG1 D265A bound mFcγRI or mFcγRIV poorly compared to 180 the mIgG2a (Fig S1B) . Notably, D+1 administration of COV2-2072 mIgG1 or COV2-2072 181 mIgG1 D265A failed to protect mice from weight loss. In contrast, COV2-2072 mIgG2a 182 prevented weight loss and reduced viral titers similarly to the human IgG1 form of COV2-2072 183 (Fig S1C-D) . These data establish the importance of Fc effector functions to antibody protection 184 when administered in a corresponding system with murine Fc regions and murine FcγRs. (Fig 5B) . A similar large number of DEGs was observed in the lungs at 8 dpi from 233 mice treated at D+2 with COV-2050 or COV2-2050 LALA-PG (Fig 5B) . Gene ontology analysis 5C, Table S2 ). Pathways unique to the COV2-2050 D+1 treatment group compared to the Prkca, and Cdc42bpa), processes that are typically associated with wound repair programs 247 (Verboon and Parkhurst, 2015) (Fig 5D) . Pathways downregulated in the COV2-2050 D+1 248 group included genes involved in type I IFN and NFκB-dependent signaling (e.g., Irf7, Stat2, 249 Nfkb2, Bst2, Isg15, and Ikbk3) (Fig 5D) , which may in part be due to the lower levels of viral 250 RNA detected (Fig 2E-F) . The expression pattern of down-or up-regulated gene sets in the 251 COV2-2050 D+1 treated animals was similar to that in naïve animals, suggesting that the intact 252 antibody limited the transcriptional changes usually seen during SARS-CoV-2 infection.

Pathways that were downregulated in the D+2 COV2-2050-treated group compared to 254 the isotype control or D+2 COV2-2050 LALA-PG-treated animals included S100A8-associated 255 innate immune signaling (e.g., Reg3g, Saa3, Itgma, Mmp8, and S100a8), oncostatin M receptor 256 associated signaling (e.g., Il6, Osmr, Csf1, and Socs3), and extracellular matrix remodeling 257 (e.g., Adamts15, Col5a1, Vcam1, and Lama4) (Fig S5, Table S2 ). Thus, COV2-2050 treatment 258 at D+2 and the resultant Fc-dependent effector responses may differentially modulate neutrophil 259 activation, gp130 signaling, and tissue damage due to matrix metalloproteinase activation. 

( Fig 6B and S6) , mature neutrophils (anti-Ly6G) (Fig 6C and S6 ) or CD8 + T cells (anti-CD8) 277 (Fig 6D and S6 ) in combination with COV2-2050 treatment at D+1. Depletion of mature 278 neutrophils, NK cells, or CD8 + T cells had no impact on weight loss in the presence of COV2-279 2050 or the isotype control mAb (Fig 6B-D) . When monocytes were depleted, COV2-2050 failed 280 to prevent the weight loss phenotype seen in non-depleted, COV2-2050-treated mice (Fig 6A) .

Monocyte depletion during COV2-2050 therapy also was associated with a loss of improvement 282 in lung pathology (Fig 6E) and higher levels of some cytokines and chemokines (CXCL10, G-283 CSF, IL-6, IFN-γ, CCL2) compared to treatment with COV2-2050 without cell depletion (Fig 6F   284 and S7). As expected, the numbers of monocytes and CD11b + DCs in the lung were lower after 285 anti-CCR2 treatment but other cell subsets were unaffected. As these myeloid cells show a less 286 inflammatory phenotype after COV2-2050 but not COV2-2050 LALA-PG treatment (Fig 4G-H) ,

FcγR engagement may shape cellular responses to limit immunopathology independently of 288 viral clearance.

Although monocyte depletion in combination with COV2-2050 treatment resulted in 290 increased weight loss, it was not associated with changes in viral RNA levels at 8 dpi (Fig 6H) , 

Consistent with observations in mice, passive transfer of intact COV2-2050 prevented weight 307 loss compared to isotype mAb-treated animals at 5 and 6 dpi, and this protection was lost in 308 animals treated with the COV2-2050 LALA-PG variant (Fig 7A) . Furthermore, hamsters treated 309 with intact COV2-2050, but not COV2-2050 LALA-PG, showed reductions in viral RNA levels at 310 6 dpi (Fig 7B) . The improved viral burden with COV2-2050 was associated with lower levels of 311 the inflammatory mediators Cxcl10, Ccl2, Ccl3, Ccl5, and Ifit3 (Fig 7C) . Thus, therapeutic 312 efficacy following neutralizing mAb administration also depends on Fc interactions in a second, Neutralizing mAbs against SARS-CoV-2 are a promising option for the treatment of (Chen et al., 2020), and the FDA granted Emergency Use Authorization to the anti-SARS-CoV-2 321 S mAbs Bamlanivimab and Casirivimab/Imdevimab for mild-to-moderately ill, high-risk patients. 

Lists of up-regulated and down-regulated genes comparing Isotype control mAb versus change values are shown.

Lead contact. Further information and requests for resources and reagents should be equipment.

Antibodies. The human antibodies studied in this paper were isolated from blood 760 samples from two individuals in North America with previous laboratory-confirmed symptomatic specimens after written informed consent were previously described (Zost et al., 2020b) and 

Passive antibody therapy in COVID-19

transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI 1111 insight 5. e142032

Antibody-dependent enhancement of infection: a mechanism for indirect 1114 virus entry into cells

Harbor Laboratory Press)

COVID 19 Vaccines: Should we fear ADE?

Studies in humanized mice and convalescent humans yield a 1121 SARS-CoV-2 antibody cocktail

A SARS-CoV-2 Infection Model in Mice 1125

Demonstrates Protection by Neutralizing Antibodies

Alveolar macrophages are critical for 1129 broadly-reactive antibody-mediated protection against influenza A virus in mice

Fc receptor but not 1134 complement binding is important in antibody protection against HIV

Monocyte differentiation and 1137 antigen-presenting functions

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

CoV-2 Mortality

Potently neutralizing and protective human 1318 antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse 1322 panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein